Literature DB >> 24333807

Trends in the use of psychotropic drugs in people with intellectual disability in Taiwan: a nationwide outpatient service study, 1997-2007.

Shang-Wei Hsu1, Po-Huang Chiang2, Yu-Chia Chang3, Jin-Ding Lin4, Ho-Jui Tung3, Chao-Yun Chen5.   

Abstract

This study aims to examine trends in outpatient psychotropic drug use among people with intellectual disabilities in Taiwan. The NHI outpatient medication records between January 1, 1997 and December 31, 2007 for people with intellectual disabilities were analyzed to observe the percent change, prevalence and prescription trends in psychotropic drugs. The overall prevalence of psychotropic medication increased from 17.82% to 23.22% during the study period. Results from stepwise logistic analysis demonstrated that females, the elderly, and individuals suffering from catastrophic disease were more prone to receive psychotropic drugs and that those with mild intellectual disability were less likely to receive psychotropic drugs. The percentage change in prescription rates of antipsychotics, hypnotics/sedatives, and antidepressants were 85.30%, 127.25%, and 167.50%, respectively, and the trends were statistically significant (p<0.05). Taiwan's NHI program and off-label use of psychotropic drugs might have attributed to this trend.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Intellectual disability; Psychotropic drugs

Mesh:

Substances:

Year:  2013        PMID: 24333807     DOI: 10.1016/j.ridd.2013.11.011

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  8 in total

1.  [Determinants of psychotropic medication in adults with mild or moderate intellectual disabilities].

Authors:  M Schützwohl; E Voss; M Stiawa; H-J Salize; B Puschner; A Koch
Journal:  Nervenarzt       Date:  2017-11       Impact factor: 1.214

2.  Pharmacogenomic Studies in Intellectual Disabilities and Autism Spectrum Disorder: A Systematic Review.

Authors:  Kazunari Yoshida; Emiko Koyama; Clement C Zai; Joseph H Beitchman; James L Kennedy; Yona Lunsky; Pushpal Desarkar; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2020-11-23       Impact factor: 5.321

3.  Dilemma of prescribing aripiprazole under the Taiwan health insurance program: a descriptive study.

Authors:  Yi-Chien Hsu; Yu-Ching Chou; Hsin-An Chang; Yu-Chen Kao; San-Yuan Huang; Nian-Sheng Tzeng
Journal:  Neuropsychiatr Dis Treat       Date:  2015-01-27       Impact factor: 2.570

4.  Antipsychotic initiation among adults with intellectual and developmental disabilities in Ontario: a population-based cohort study.

Authors:  Tara Gomes; Wayne Khuu; Mina Tadrous; Simone Vigod; Virginie Cobigo; Yona Lunsky
Journal:  BMJ Open       Date:  2019-07-30       Impact factor: 2.692

5.  Community-Based Support and Social Services and Their Association with Frailty Factors in Older People with Intellectual Disability and Affective and Anxiety Disorders: A Swedish National Population-Based Register Study.

Authors:  Nadia El Mrayyan; Christina Bökberg; Jonas Eberhard; Gerd Ahlström
Journal:  Community Ment Health J       Date:  2021-11-08

6.  Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study.

Authors:  Rory Sheehan; Angela Hassiotis; Kate Walters; David Osborn; André Strydom; Laura Horsfall
Journal:  BMJ       Date:  2015-09-01

7.  Experiences of psychotropic medication use and decision-making for adults with intellectual disability: a multistakeholder qualitative study in the UK.

Authors:  Rory Sheehan; Angela Hassiotis; André Strydom; Nicola Morant
Journal:  BMJ Open       Date:  2019-11-27       Impact factor: 2.692

8.  Off-label use of antipsychotic medications in psychiatric inpatients in China: a national real-world survey.

Authors:  Juan Wang; Feng Jiang; Yating Yang; Yulong Zhang; Zhiwei Liu; Xiaorong Qin; Xueqin Tao; Tingfang Liu; Yuanli Liu; Yi-Lang Tang; Huanzhong Liu; Robert O Cotes
Journal:  BMC Psychiatry       Date:  2021-07-27       Impact factor: 3.630

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.